Recent GAAPP Publications and Conference Presentations
Relevant News
From the Chief Scientific Officer Desk
Research News and Opportunities
Recruiting Research Opportunities
COPD
In honor of “World COPD Day” in November, we added an educational page about participating in clinical trials for COPD to our website. Learn more here.
Asthma
Clinical Trial Recruitment: Help researchers test a modified asthma inhaler with an approximately 90% lower carbon footprint.
Inclusion criteria:
Mild to moderate asthma
18 years or older
Lives in US, Canada or Latin America
Click here to see if you are eligible to participate!
Advisory Board: Looking for 6-8 patients with uncontrolled asthma in the UK and EU
Inclusion Criteria:
18 years old or older
Speaks English
Lives in Europe or the United Kingdom
Willing to provide feedback on the direction of asthma research and the unmet needs in the asthma community
Email research@gaapp.org if interested in lending your voice to research!
Bronchiectasis
Bronchiectasis Understanding and Research on Daily Experiences and Needs or The BURDEN initiative is a research project to examine the impact of Non-Cystic Fibrosis Bronchiectasis (NCFBE) on the everyday life of people living with NCFBE and their caregivers. It is also commonly referred to as bronchiectasis (without cystic fibrosis) or just bronchiectasis. Bronchiectasis is a chronic, often progressive lung disease characterized by irreversible and abnormal widening of the bronchi and chronic symptoms.
For more information, click here!
Chronic Cough
Advisory Board: Looking for 3 patients with a recurrent chronic cough in Germany, Italy and Spain
Inclusion criteria:
18 years or older
Speaks English
Lives in Germany, Italy or Spain
Willing to provide feedback on chronic cough
Email research@gaapp.org if interested in lending your voice to research!
GAAPP Publications and Conference Presentations
GAAPP participated in GOLD 2024 November 12-13th in Philadelphia as Silver sponsors; we had a well-attended booth to educate others about the CAAT and “Speak Up for COPD”. You can read more about the conference below in the segment, From the Chief Scientific Officer Desk.
Our CEO also co-authored the following publications this month:
Our CSO Dr. Ruth Tal-Singer co-authored the following publications on collaborative projects she participated in:
Román-Rodríguez M, McMullan I, Warner M, Compton CH, Tal-Singer R, Orlow JM, Han MK. Perspectives on Treatment Decisions, Preferences, and Adherence and Long-Term Management in Asthma and COPD: A Qualitative Analysis of Patient, Caregiver, and Healthcare Provider Insights.Patient Prefer Adherence. 2024;18:2295-2306
Harvey-Dunstan TC, Baldwin MM, Tal-Singer R, et al. The Responsiveness of Exercise Tests in COPD: A Randomized Controlled Trial.Chest. Published online August 21, 2024. [https://doi:10.1016/j.chest.2024.05.051] doi:10.1016/j.chest.2024.05.051
Aksamit TR, Locantore N, Addrizzo-Harris D, et al. Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients.Am J Respir Crit Care Med. 2024;210(1):108-118.
The CAAT Governance Board met in November to discuss several efforts including a revision to the User Guide that will be translated to 3 languages, thanks to a grant from Sanofi. The revised guide is now available on our website and translations are in progress.
A Russian translation of the CAAT and an updated list of Industry members to the advisory panel were added to our webpage.
An educational postcard on the CAAT (containing links to a video about application in asthma and the revised User Guide) was supported by AstraZeneca and Chiesi was posted on our webpage and distributed to all attendees of GOLD 2024 in Philadelphia.
From the Chief Scientific Officer Desk
Our President Tonya Winders and the Research and Education team attended the GOLD 2024 conference in Philadelphia and enjoyed meeting many collaborators, Speaking Up for COPD and spreading the word on the renaming of the COPD assessment test (CAT) to Chronic Airways Assessment Test (CAAT) to reflect its use in people with other lung conditions including asthma. The new name is mentioned in GOLD 2025.
We heard about revisions to GOLD 2025 and about recently approved treatments including the first Biologic therapy for COPD in many countries and a new nebulized treatment (in the US) that offer people with COPD and their care team new options.
I was honored to moderate the session “Industry Pipeline: Upcoming Novel Treatments for Patients With COPD” on Tuesday 12 November where we also heard about the promise of future treatments for unmet needs for people with COPD.
We are grateful to all involved in the development of these approved and future therapies. We would not be hearing about new treatments for COPD if not for the participation of patients in clinical trials, focus groups, surveys, and advisory boards or the dedication of many researchers and regulators around the world. For more information on the importance of participation in clinical trials for COPD: https://gaapp.org/copd-clinical-trials-education/
